CN115768433A - 含有司培前列素的医药制剂 - Google Patents

含有司培前列素的医药制剂 Download PDF

Info

Publication number
CN115768433A
CN115768433A CN202180044806.9A CN202180044806A CN115768433A CN 115768433 A CN115768433 A CN 115768433A CN 202180044806 A CN202180044806 A CN 202180044806A CN 115768433 A CN115768433 A CN 115768433A
Authority
CN
China
Prior art keywords
glaucoma
ocular hypertension
pharmaceutical preparation
treatment
spoprost
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180044806.9A
Other languages
English (en)
Chinese (zh)
Inventor
山元誉子
谷口孝纯
岛崎敦
木村惠利香
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of CN115768433A publication Critical patent/CN115768433A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180044806.9A 2020-08-13 2021-08-12 含有司培前列素的医药制剂 Pending CN115768433A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020136796 2020-08-13
JP2020-136796 2020-08-13
PCT/JP2021/029701 WO2022034909A1 (ja) 2020-08-13 2021-08-12 セペタプロストを含有する医薬製剤

Publications (1)

Publication Number Publication Date
CN115768433A true CN115768433A (zh) 2023-03-07

Family

ID=80248014

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180044806.9A Pending CN115768433A (zh) 2020-08-13 2021-08-12 含有司培前列素的医药制剂

Country Status (7)

Country Link
US (1) US20230285411A1 (cg-RX-API-DMAC7.html)
EP (1) EP4197540A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2022034909A1 (cg-RX-API-DMAC7.html)
KR (1) KR20230051199A (cg-RX-API-DMAC7.html)
CN (1) CN115768433A (cg-RX-API-DMAC7.html)
TW (1) TW202220666A (cg-RX-API-DMAC7.html)
WO (1) WO2022034909A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202404569A (zh) 2022-04-22 2024-02-01 日商參天製藥股份有限公司 含有賽佩普斯特(Sepetaprost)之眼科用組合物
TW202517277A (zh) * 2023-10-10 2025-05-01 日商參天製藥股份有限公司 含有賽佩普斯特(Sepetaprost)之點眼液

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102498105A (zh) * 2009-07-28 2012-06-13 小野药品工业株式会社 双环化合物及其医疗用途
CN111526876A (zh) * 2017-12-28 2020-08-11 参天制药株式会社 含有吡啶基氨基乙酸化合物的药物制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011013651A (ja) 2009-07-03 2011-01-20 Mitsumasa Maeda フレキシブルディスプレイのれん
WO2019124489A1 (ja) * 2017-12-21 2019-06-27 参天製薬株式会社 セペタプロストとep2アゴニストとの組み合わせ医薬
EP3730138B1 (en) * 2017-12-21 2024-02-14 Santen Pharmaceutical Co., Ltd. Combination of sepetaprost and ripasudil for use in the prophylaxis or treatment of glaucoma or ocular hypertension
JP2022508715A (ja) * 2018-10-15 2022-01-19 オキュフィア・ファーマ・インコーポレイテッド 緑内障および関連状態の処置のための方法および組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102498105A (zh) * 2009-07-28 2012-06-13 小野药品工业株式会社 双环化合物及其医疗用途
CN111526876A (zh) * 2017-12-28 2020-08-11 参天制药株式会社 含有吡啶基氨基乙酸化合物的药物制剂

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KOÇLUK Y,等: "Efficacy of Monotherapy with Either Bimatoprost or Travoprost in Patients with Primary Open-Angle Glaucoma Resistant to Latanoprost Therapy", TURK J OPHTHALMOL, vol. 41, no. 5, 31 October 2011 (2011-10-31), pages 295 - 298, XP009534908, DOI: 10.4274/tjo.41.36844 *
MILLER ELLIS E,等: "Ocular hypotensive effect of the novel EP3/FP agonist ONO-9054 versus Xalatan: results of a 28-day, double-masked, randomised study", BR J OPHTHALMOL, vol. 101, no. 6, 20 September 2016 (2016-09-20), pages 797 *
YAMANE S,等: "IOP-Lowering Effect of ONO-9054, A Novel Dual Agonist of Prostanoid EP3 and FP Receptors, in Monkeys", INVEST OPHTHALMOL VIS SCI, vol. 56, no. 4, 30 April 2015 (2015-04-30), pages 2548, XP055765498, DOI: 10.1167/iovs.14-16181 *

Also Published As

Publication number Publication date
JPWO2022034909A1 (cg-RX-API-DMAC7.html) 2022-02-17
EP4197540A4 (en) 2024-06-19
KR20230051199A (ko) 2023-04-17
TW202220666A (zh) 2022-06-01
US20230285411A1 (en) 2023-09-14
WO2022034909A1 (ja) 2022-02-17
EP4197540A1 (en) 2023-06-21

Similar Documents

Publication Publication Date Title
JP6383058B2 (ja) スルホンアミド化合物の組み合わせ
JP4934653B2 (ja) Rhoキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤
JP2023110030A (ja) セペタプロストとRhoキナーゼ阻害剤との組み合わせ医薬
TW202220666A (zh) 含有賽佩普斯特(sepetaprost)之醫藥製劑
US11666563B2 (en) Pharmaceutical preparation containing pyridyl aminoacetic acid compound
CN111491636A (zh) 奥米帕格的组合
HK40102807A (en) Combination of sepetaprost and netarsudil for use in the prophylaxis or treatment of glaucoma or ocular hypertension
HK40102807B (en) Combination of sepetaprost and netarsudil for use in the prophylaxis or treatment of glaucoma or ocular hypertension
HK40029828A (en) Omidenepag combination
EA043474B1 (ru) Комбинация омиденепага
HK40025370A (en) Omidenepag combination
HK40024494A (en) MEDICAMENT COMPRISING COMBINATION OF SEPETAPROST AND Rho-KINASE INHIBITOR
HK40029829B (en) Combination of sepetaprost and ripasudil for use in the prophylaxis or treatment of glaucoma or ocular hypertension
HK40031074A (en) Pharmaceutical preparation containing pyridyl aminoacetic acid compound
EA050493B1 (ru) ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ КОМБИНАЦИЮ СЕПЕТАПРОСТА И ИНГИБИТОРА Rho-АССОЦИИРОВАННОЙ ПРОТЕИНКИНАЗЫ, СОДЕРЖАЩЕЙ СУПЕРСПИРАЛЬ
JP2000336042A (ja) 眼圧下降剤
JP2003531853A (ja) 眼圧降下剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination